Pesquisas alternativas:
cancers compared » cancer compared (Expandir a Pesquisa), carriers compared (Expandir a Pesquisa), runners compared (Expandir a Pesquisa)
drugs compared » drugs combined (Expandir a Pesquisa), pigs compared (Expandir a Pesquisa), drugs comparison (Expandir a Pesquisa)
acyl compared » acl compared (Expandir a Pesquisa), nacl compared (Expandir a Pesquisa), al compared (Expandir a Pesquisa)
compared law » compared a (Expandir a Pesquisa), compared _ (Expandir a Pesquisa), company law (Expandir a Pesquisa)
compared can » compared case (Expandir a Pesquisa), compared a (Expandir a Pesquisa), compared cases (Expandir a Pesquisa)
3 cancers » 13 cancers (Expandir a Pesquisa), 30 cancers (Expandir a Pesquisa), 32 cancers (Expandir a Pesquisa)
law non » law note (Expandir a Pesquisa), thaw non (Expandir a Pesquisa)
can non » dan non (Expandir a Pesquisa), than non (Expandir a Pesquisa), can ngoc (Expandir a Pesquisa)
1 drugs » _ drugs (Expandir a Pesquisa), 1 drug (Expandir a Pesquisa)
cancers compared » cancer compared (Expandir a Pesquisa), carriers compared (Expandir a Pesquisa), runners compared (Expandir a Pesquisa)
drugs compared » drugs combined (Expandir a Pesquisa), pigs compared (Expandir a Pesquisa), drugs comparison (Expandir a Pesquisa)
acyl compared » acl compared (Expandir a Pesquisa), nacl compared (Expandir a Pesquisa), al compared (Expandir a Pesquisa)
compared law » compared a (Expandir a Pesquisa), compared _ (Expandir a Pesquisa), company law (Expandir a Pesquisa)
compared can » compared case (Expandir a Pesquisa), compared a (Expandir a Pesquisa), compared cases (Expandir a Pesquisa)
3 cancers » 13 cancers (Expandir a Pesquisa), 30 cancers (Expandir a Pesquisa), 32 cancers (Expandir a Pesquisa)
law non » law note (Expandir a Pesquisa), thaw non (Expandir a Pesquisa)
can non » dan non (Expandir a Pesquisa), than non (Expandir a Pesquisa), can ngoc (Expandir a Pesquisa)
1 drugs » _ drugs (Expandir a Pesquisa), 1 drug (Expandir a Pesquisa)
1
Por Moshal, Karni S., Ferri-Lagneau, Karine F., Haider, Jamil, Pardhanani, Pooja, Leung, TinChung
Publicado em 2011
“...13). Non-tumorigenic 3T3-L1 cells served as negative control. The cells were grafted near...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
Por Ramaswamy, Chitra, Westheimer, Emily, Braunstein, Sarah
Publicado no Open Forum Infect Dis (2017)
“...; 15.4%) and cardiovascular disease (n = 3,724, 10.9%). The top three causes of non-HIV-related cancer...”Publicado no Open Forum Infect Dis (2017)
Obter o texto integral
Obter o texto integral
Artigo
3
Por Arthur, Susan Tsivitse, Noone, Joshua M, Van Doren, Bryce A, Roy, Debosoree, Blanchette, Christopher M
Publicado em 2014
“... in their non-cachexia peers. Hospitalizations associated with cachexia had an increased LOS compared to non...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
“... rearrangements (1–2% of tumors, drug: crizotinib) and BRAF-V600E mutations (1–3% of tumors, drugs: vemurafenib...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por Klement, Giannoula L., Goukassian, David, Hlatky, Lynn, Carrozza, Joseph, Morgan, James P., Yan, Xinhua
Publicado em 2012
“...The HER2-PI3K pathway is the one of the most mutated pathways in cancer. Several drugs targeting...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Liang, Guanzhao, Liu, Musang, Wang, Qiong, Shen, Yongnian, Mei, Huan, Li, Dongmei, Liu, Weida
Publicado no Oncotarget (2017)
“..., compared to non-itraconazole-treated mice. Also, itraconazole can significantly inhibit cell proliferation...”Publicado no Oncotarget (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Shen, Yuanyuan, Pi, Zhaoke, Yan, Fei, Yeh, Chih-Kuang, Zeng, Xiaojun, Diao, Xianfen, Hu, Yaxin, Chen, Siping, Chen, Xin, Zheng, Hairong
Publicado no Int J Nanomedicine (2017)
“... that a 2-fold higher drug concentration had accumulated in the glioblastoma 3 h after FUS treatment...”Publicado no Int J Nanomedicine (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Adams, David J., Waud, William R., Wani, Mansukh C., Manikumar, Govindarajan, Flowers, James L., Driscoll, Timothy A., Morgan, Lee Roy
Publicado em 2010
“... for human neuroblastoma (IMR-32), colon (HT29), ovarian (SK-OV-3), pancreatic (Panc-1), glioma (SF-295...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por James P. McCusker, Michel Dumontier, Rui Yan, Sylvia He, Jonathan S. Dordick, Deborah L. McGuinness
Publicado em 2017-02-01
Assuntos:
“...Drug repositioning...”Publicado em 2017-02-01
Obter o texto integral
Artigo
10
Assuntos:
“...Colorectal Cancer...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Por Du, Yang, Zhang, Qian, Jing, Lijia, Liang, Xiaolong, Chi, Chongwei, Li, Yaqian, Yang, Xin, Dai, Zhifei, Tian, Jie
Publicado no Int J Nanomedicine (2015)
“...-associated angiogenesis is an important goal in cancer therapy. However, the efficient delivery of drugs...”Publicado no Int J Nanomedicine (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
13
“... cancers, functions as an efflux pump for non-polar drugs, powered by the hydrolysis of ATP at its...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
Por Hsueh Wei-Ting, Wu Annie, Monie Archana, Hoory Talia, Kim Daejin, Pai Sara I, Hung Chien-Fu
Publicado em 2010-07-01
“... in improved survival compared to the non drug-loaded irradiated MOSEC cells. Furthermore, we showed...”Publicado em 2010-07-01
Obter o texto integral
Artigo
15
Por Huang, He, Yang, Da-Peng, Liu, Minghuan, Wang, Xiangsheng, Zhang, Zhiyong, Zhou, Guangdong, Liu, Wei, Cao, Yilin, Zhang, Wen Jie, Wang, Xiansong
Publicado no Int J Nanomedicine (2017)
“... of 0–100 μg/mL, which can therefore be used as a safe drug delivery carrier. Furthermore, compared...”Publicado no Int J Nanomedicine (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Wu, Sheng-Kai, Chiang, Chi-Feng, Hsu, Yu-Hone, Lin, Tzu-Hung, Liou, Houng-Chi, Fu, Wen-Mei, Lin, Win-Li
Publicado em 2014
“... of pegylated liposomal doxorubicin (PLD) for brain metastasis of breast cancer. Murine breast cancer 4T1-luc2...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
18
Por Chen, Shuo, Jiao, Jin-Wen, Sun, Kai-Xuan, Zong, Zhi-Hong, Zhao, Yang
Publicado no Drug Des Devel Ther (2015)
“... of this study was to investigate the role of miR-133b in the development of drug resistance in ovarian cancer...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Ratnayake, Wishrawana S., Apostolatos, André H., Ostrov, David A., Acevedo-Duncan, Mildred
Publicado no Int J Oncol (2017)
“... have investigated the effects of two novel aPKC inhibitors; 2-acetyl-1,3-cyclopentanedione (ACPD...”Publicado no Int J Oncol (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Singh, Saurabh, Chitkara, Deepak, Mehrazin, Reza, Behrman, Stephen W., Wake, Robert W., Mahato, Ram I.
Publicado em 2012
“... cancer tissue possess a distinct SP fraction. Nearly 75% of the SP cells are in the G0/G1 phase compared...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo